Vaxart Stock (NASDAQ:VXRT), Trade Ideas

Vaxart

Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

AMSC

CONNEXA SPORTS TECH INC by Connexa Sports Technologies Inc.

CNXA

DCGO

ENSC

EVAX

EVTV

EXTR

GNPX

GOOG

GOOGL

ALPS ETF Trusthen & Steers Global Realty Majors ETF

HTLF

KUKE

MARK

MINM

MKTX

NVVE

NYCB

NYXH

OBLG

PARA

PLUG

POWL

REVB

RVSN

SLDB

SNPX

TRIB

TSVT

VXRT

ZJYL

Shares of Advanced Micro Devices, Inc. (NASDAQ: AMD) shares declined 3.8% to $165.49 following fourth-quarter results.

AMD reported fourth-quarter non-GAAP earnings per share of 77 cents per share on revenue of $6.17 billion.

AMD shares dipped 3.8% to $165.49 on Wednesday.

Why AMD Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

eye-6318412

Vaxart shares are trading higher by around 8% Wednesday afternoon. The company recently secured a contract from the U.S. Government via the Department of Health and Human Services.

What&#39;s Going On With Vaxart Stock Today?

vaccine-4892059

Vaxart shares are trading higher by 17.8% Tuesday morning amid multiple news items. The company recently secured a contract from the U.S. Government via the Department of Health and Human Services.

What&#39;s Going On With Vaxart (VXRT) Stock?

Vaxart Inc

Starting your first job is an exhilarating step into adulthood, complete with new responsibilities and financial freedoms. However, with great power (read: paycheck) comes great responsibility. 
Here are six crucial money management tips I wish someone had whispered in my ear as I signed my first employment contract. 
Budgeting Isn&#8217;t Just a Buzzword
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="585" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/24020912/image-175-1024x585.png" alt="" class="wp-image-305779" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/24020912/image-175-1024x585.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/24020912/image-175-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/24020912/image-175-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/24020912/image-175-1536x878.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/24020912/image-175.png 1792w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Tracking every penny with a budget is important. Image Generated Via Dall-E</figcaption></figure>
It sounded so tedious at first—tracking every penny? Really? But creating a budget was a game changer. It helped me understand where my money was going and highlighted areas where I could cut back without feeling strapped. Plus, seeing a plan on paper (or an app) made my financial goals much more attainable.
Emergency Funds: Your Financial Safety Net
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="585" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/24020926/image-176-1024x585.png" alt="" class="wp-image-305780" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/24020926/image-176-1024x585.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/24020926/image-176-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/24020926/image-176-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/24020926/image-176-1536x878.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/24020926/image-176.png 1792w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Emergency funds act as a safety net and a lifesaver, Image Generated Via Dall-E</figcaption></figure>
One word: Lifesaver. I never anticipated the random expenses that could pop up—like a broken-down car or a sudden job loss. Building an emergency fund isn't the most thrilling part of getting a paycheck, but it's definitely one of the smartest. It's all about peace of mind.
Understand Your Taxes
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="585" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/24035935/image-182-1024x585.png" alt="" class="wp-image-305934" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/24035935/image-182-1024x585.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/24035935/image-182-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/24035935/image-182-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/24035935/image-182-1536x878.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/24035935/image-182.png 1792w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Taxes come as a shock if you are not prepared for them, Image Generated Via Dall-E</figcaption></figure>
The first time I saw my paycheck, I was baffled by how much less I was taking home than I expected. Understanding how taxes work, what tax bracket you're in, and potential deductions can really help maximize your earnings and prevent those nasty surprises come tax season.
Retirement Plans Are Not Just for the Old
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="585" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/24035503/image-181-1024x585.png" alt="" class="wp-image-305930" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/24035503/image-181-1024x585.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/24035503/image-181-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/24035503/image-181-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/24035503/image-181-1536x878.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/24035503/image-181.png 1792w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Retirement is closer than you think, start preparing early. Image Generated Via Dall-E</figcaption></figure>
The word &#8216;retirement&#8217; seemed so far off it was practically in another galaxy. But starting to save early takes advantage of compound interest and can significantly impact your financial security in the future. Enrolling in a 401(k) and getting that employer match is like getting free money.
Credit Cards: Handle With Care
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="585" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/24021012/image-179-1024x585.png" alt="" class="wp-image-305783" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/24021012/image-179-1024x585.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/24021012/image-179-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/24021012/image-179-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/24021012/image-179-1536x878.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/24021012/image-179.png 1792w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Credit Cards are not free money and should be used with caution, Image Generated Via Dall-E</figcaption></figure>
They're not free money—something I learned the hard way. Using a credit card responsibly can help build your credit score, which is crucial for future loans for big purchases like a home. But it&#8217;s easy to fall into the debt trap if you're not careful.
Financial Education is Continuous
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="585" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/24021015/image-180-1024x585.png" alt="" class="wp-image-305784" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/24021015/image-180-1024x585.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/24021015/image-180-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/24021015/image-180-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/24021015/image-180-1536x878.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/24021015/image-180.png 1792w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Every stage of life brings new financial challenges and opportunities. Continuously educating yourself about personal finance—from reading articles to using financial tools—can empower you to make informed decisions and stay ahead of the game.
Read Next: <a href="https://www.benzinga.com/markets/equities/24/04/38345502/elon-musk-reacts-after-nvidia-stock-plunges-10-and-erases-212b-market-cap-rookie-numbers?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Reacts After Nvidia Stock Plunges 10% And Erases $212B Market Cap: &#8216;Rookie Numbers&#8217;</a>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

My First Pay Check Didn't Open My Eyes, But The Second One Taught Me A Great Deal About Money — Here Are 6 Things You Should Know

Danfoss Has Chosen HPE GreenLake For SAP S/4HANA Cloud Within The RISE With SAP Program And Deployed In Danfoss Data Centers To Accelerate The Company's Sustainable Cloud Journey

Macro Economic Events

Econ #s

Economics

Germany Ifo Business Climate Index For April 89.4 Vs. 88.9 Est.; 87.9 (Revised) Prior

Germany Current Assessment For April 88.9 Vs. 88.7 Est.; 88.1 Prior

Germany Business Expectations For April 89.9 Vs. 88.9 Est.; 87.7 (Revised) Prior

ALVO

Alvotech Announced Positive Topline Results From A Confirmatory Clinical Study For AVT05, Alvotech's Proposed Biosimilar To Simponi And Simponi Aria (golimumab)

In the latest development, Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) has reportedly projected a slower increase in the production and delivery of its 787 widebody jets. This is primarily due to supplier shortages,
What Happened: Scott Stocker, the 787 vice president and general manager, disclosed the situation to employees at the South Carolina facility via a memo on Monday, Reuters reported. Despite the hurdles, Boeing is determined to incrementally increase its rate to cater to the &#8220;strong demand&#8221;.
The memo highlighted, &#8220;We continue to manage through supplier shortages on a few key parts.&#8221; 
It also mentioned that customers have been notified about the anticipated slower increase in production and deliveries.
The Federal Aviation Administration (FAA) is keeping a close watch on Boeing&#8217;s challenges in procuring certain parts and is in constant communication with the company. The agency&#8217;s primary concern is to ensure that only safe and compliant airplanes are dispatched from the factory.
See Also: <a href="https://www.benzinga.com/news/24/04/38347033/bound-by-courtroom-rules-donald-trump-is-doing-something-uncommon-for-his-public-persona-staying-sil?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Bound By Courtroom Rules, Donald Trump Is Doing Something Uncommon For His Public Persona: Staying Silent</a>
Boeing, scheduled to announce earnings on Wednesday, is facing scrutiny over the manufacturing of its 777 and 787 widebody jets. This comes in the wake of allegations by company engineer Sam Salehpour at a U.S. Senate hearing last week, who pointed out inadequate shimming in some areas of the 787 Dreamliner.
Furthermore, the company&#8217;s separate production of its 737 MAX single-aisle jet in Washington state has experienced a significant decline, as U.S. regulators tighten factory inspections and workers slow down the assembly line to complete outstanding work.
A Boeing spokesperson confirmed to <a href="https://pro.benzinga.com">Benzinga</a> about the memo but refrained from divulging further details.
Why It Matters: The latest development comes on the heels of <a href="https://www.benzinga.com/markets/equities/24/04/38330613/boeing-grapples-with-32-whistleblower-complaints-in-3-years-amid-mounting-safety-concerns-report">32 whistleblower complaints</a> against Boeing over the past three years, with allegations of employer retaliation being investigated by the U.S. workplace safety regulator. This has raised significant safety concerns for the company.
Moreover, as Boeing<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38365885/boeing-will-deliver-q1-earnings-while-at-center-of-air-safety-scandal-everybody-wan"> prepares to release its Q1 earnings</a>, investors are keen to see if the company&#8217;s performance can offset the recent scandals that have tarnished its public image.
Price Action: On Monday, the stock closed at 170.48, with a slight increase of 0.22% from the previous close.
Read Next: <a href="https://www.benzinga.com/markets/equities/24/04/38346938/trump-is-a-force-of-nature-reince-priebus-has-raised-70m-for-gop-convention-despite-being-pushed?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">&#8216;Trump Is A Force of Nature&#8217;: Reince Priebus Has Raised $70M For GOP Convention Despite Being Pushed Out</a>
Photo via Shutterstock
Editor's note: This story has been updated with a comment from Boeing on the aforementioned memo
<div style="font-family: 'Lato', sans-serif">
<div>
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by Benzinga Neuro, Edited by 
 <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Pooja Rajkumari</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>
</div>

Equities

General

Boeing Foresees Slower 787 Production Ramp-Up Due To Supplier Shortages: Report (UPDATED)

Elon Musk, the CEO of Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), has expressed his dissatisfaction with the term GPU while announcing that the company&#8217;s core AI infrastructure is no <a href="https://www.benzinga.com/news/23/08/34128510/elon-musk-affirms-training-compute-will-not-be-a-constraint-for-teslas-full-self-driving-improvement">longer training-constrained</a>.
What Happened: During the <a href="https://www.benzinga.com/news/earnings/24/04/38390883/tesla-q1-earnings-highlights-ev-giant-misses-wall-street-estimates-makes-cost-cuts-invests-in-ai-sp">first-quarter earnings call</a> on Tuesday, Musk revealed that Tesla has been actively expanding its core AI infrastructure. He stated, &#8220;We are, at this point, no longer training-constrained, and so we&#8217;re making rapid progress.&#8221;
The tech billionaire also disclosed that Tesla has installed and <a href="https://www.benzinga.com/news/24/04/38111017/tesla-ceo-elon-musk-disagrees-with-nvidias-jensen-huang-that-anyone-can-make-their-own-neural-networ">commissioned 35,000 H100</a> computers or GPUs and Tesla anticipates this number to potentially reach around 85,000 by the end of the year, primarily <a href="https://www.benzinga.com/markets/equities/24/01/36707594/not-clear-quips-elon-musk-as-tesla-enthusiast-questions-metas-plan-to-buy-nvidias-ai-chips-equiv">for training purposes</a>. 
See Also: <a href="https://www.benzinga.com/news/24/04/38395385/elon-musk-says-tesla-optimus-humanoid-robot-might-be-available-externally-by-the-end-of-next-year-he">Elon Musk Says Tesla Optimus Humanoid Robot Might Be Available Externally By The End Of Next Year: Here&#8217;s The Progress Report</a>
&#8220;We are making sure that we&#8217;re being as efficient as possible in our training,&#8221; Musk said, adding that it is not just about the number of H100s but &#8220;how efficiently they&#8217;re used.&#8221; 
During the conversation, Musk also expressed his discomfort with the term GPU. &#8220;I always feel like a wince when I say GPU because it&#8217;s not. GPU stand — G stands for graphics, and it doesn&#8217;t do graphics,&#8221; the tech mogul stated. 
&#8220;GPU is [the] wrong word,&#8221; he said, adding, &#8220;They need a new word.&#8221;
Subscribe to the <a href="https://bztechtrends.beehiiv.com/subscribe">Benzinga Tech Trends newsletter</a> to get all the latest tech developments delivered to your inbox.
Why It Matters: Musk&#8217;s statement came after Tesla reported its first-quarter financial revenue of $21.0 billion, which showed a 9% year-over-year decrease, missing the Street consensus estimate of $22.15 billion. The company stated that its revenue was affected by reduced average selling prices and decreased vehicle deliveries during the quarter.
On the other hand, Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) last year made a significant impact on the AI and computing sectors by introducing its H100 data center chip, which added more than $1 trillion to the company&#8217;s overall value. 
In February, earlier this year, it was reported that the demand for the H100 chip, which is four times faster than its predecessor, the A100, in training large language models or LLMs and 30 times faster in responding to user prompts, has been so substantial that customers are <a href="https://www.benzinga.com/government/24/02/37283133/nvidias-h100-chip-sparks-ai-revolution-boosting-value-by-1t-as-it-unveils-new-chips-for-china">encountering wait times of up to six months</a>.
Meanwhile, earlier this month, Piper Sandler&nbsp;analyst <a href="https://www.benzinga.com/news/24/04/38257652/nvidias-hopper-demand-and-blackwell-launch-position-makes-it-a-top-large-cap-pick-analysts">Harsh V. Kumar</a> engaged directly with Nvidia's management team and reported that despite Nvidia&#8217;s Hopper GPU being on the market for almost two years, demand remains strong, outstripping supply. <a href="https://www.benzinga.com/news/24/04/38257652/nvidias-hopper-demand-and-blackwell-launch-position-makes-it-a-top-large-cap-pick-analysts">Customers are hesitant to shift their orders</a> from the Hopper to the Blackwell, fearing extended wait times due to anticipated supply limitations.
Check out more of Benzinga&#8217;s Future Of Consumer Tech by <a href="https://www.benzinga.com/topic/consumer-tech">following this link.</a>
Read Next: <a href="https://www.benzinga.com/general/gaming/24/04/38395097/elon-musk-likes-games-originating-from-this-country-because-because-they-havet-been-corrupted-by-w">Elon Musk Likes Games Originating From This Country Because They Haven&#8217;t Been Corrupted By &#8216;Woke DEI Lies&#8217;</a>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Photo via Shutterstock

Tech

NVDA

TSLA

Tesla CEO Elon Musk Says He Feels 'Like A Wince' When Saying 'GPU' As He Boasts Rapid Progress With AI Compute: 'Need A New Word'

Calliditas Therapeutics AB&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALT#NASDAQ">CALT</a>), (NASDAQ&nbsp;STOCKHOLM: CALTX)&nbsp;(&quot;Calliditas&quot;) today announced that the global open-label extension (OLE) study to the Phase 3 NefIgArd study showed a treatment response consistent with the NefIgArd study across endpoints of urine protein to creatinine ration (UPCR) and estimated glomerular filtration rate (eGFR) at 9 months across all IgAN patients, including those who had previously received Nefecon in the NefIgArd study.

CALT

Calliditas Announces NefIgArd Open Label Extension Results

Earnings

Evotec Fiscal 2023 Revenue $848.644M Up From $816.11M YoY, Adjusted EBITDA $$.06M

&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4148234-1&amp;h=2946051148&amp;u=https%3A%2F%2Fclarivate.com%2F&amp;a=Clarivate+Plc" target="_blank">Clarivate Plc</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLVT#NYSE">CLVT</a>), a leading global provider of transformative intelligence, today announces it has signed the&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4148234-1&amp;h=1345612360&amp;u=https%3A%2F%2Fwww.un.org%2Fsustainabledevelopment%2Fsdg-publishers-compact%2F&amp;a=United+Nations+Sustainable+Development+Goals+(UN+SDGs)+Publishers+Compact." target="_blank">United Nations Sustainable Development Goals (UN SDGs) Publishers Compact.</a>&nbsp;Signatories of the compact pledge to develop sustainable practices and act as champions of the SDGs during the&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4148234-1&amp;h=3871956681&amp;u=https%3A%2F%2Fwww.un.org%2Fsustainabledevelopment%2Fdecade-of-action%2F&amp;a=Decade+of+Action" target="_blank">Decade of Action</a>&nbsp;(2020-2030).

Government

Regulations

CLVT

Clarivate joins United Nations Sustainable Development Goals (UN SDGs) Publishers Compact

Suzano Ventures, the corporate venture capital arm of Suzano, the world&#39;s largest market pulp producer, has made a strategic investment into the Canadian materials science startup, Bioform Technologies. The investment provides up to US$5 million towards the company&#39;s seed round, enabling it to accelerate the development of its novel bio-based plastic alternatives. The products can be manufactured through modified industrial processes already used in the pulp and paper sector.
Bioform&#39;s proprietary technology rapidly produces wood pulp-reinforced hydrogels to create high-performance plastic alternatives, which can be made using Suzano&#39;s wood pulp fibre as a key input. Bioform&#39;s materials have the potential to be home compostable or recycled through existing paper recycling processes and do not require fossil-based inputs. The technology is highly versatile and has a number of applications where it could replace conventional single-use plastics, including paper recyclable thermoformable films for packaging applications and compostable heat-sealable films for pouches, agriculture, and garbage bags.
With the potential to offer an&nbsp;80 percent&nbsp;lower carbon footprint than conventional single-use plastics, Bioform&#39;s technology has similar or enhanced product performance to conventional plastics in areas such as tensile strength and permeability for oxygen or water vapor.

Suzano Ventures Invests Up To $5M Into Bioform Technologies To Further Develop Bio-based Plastic Alternatives

First&nbsp;non-immunosuppressive therapy for the treatment of IgA Nephropathy (IgAN) approved in&nbsp;Europe
Conditional marketing authorization is based on statistically significant and clinically meaningful results from the phase-III PROTECT trial

TVTX

CSL Vifor And Travere Therapeutics Granted European Commission Conditional Marketing Authorization For FILSPARI (Sparsentan) For The Treatment Of IgA Nephropathy

Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) senior executive Lars Moravy on Tuesday clarified that the company is not inhibited by 4680 cell production to ramp Cybertrucks. 
What Happened: As compared to the previous quarter, 4680 cell production in the first quarter rose by about 18% to 20%, Moravy said during Tesla&#8217;s first-quarter earnings call. In March, the company produced enough cells <a href="https://www.benzinga.com/news/24/03/37863738/tesla-smashes-doubts-about-4680-cell-production-says-its-made-enough-batteries-for-1-000-cybertrucks">for over 1000 Cybertrucks</a> at Giga Texas in a week. 
&#8220;We expect to stay ahead of the Cybertruck ramp with the cell production throughout Q2,&#8221; Moravy said while adding that the company is looking to maintain multiple weeks of cell inventory to make sure it&#8217;s ahead of Cybertruck&#8217;s production ramp. However, the cell production will be in tandem with Cybertruck production, he noted
&#8220;We&#8217;re not going to just randomly build 4680s unless we have a place to put them and so we&#8217;re going to make sure we&#8217;re prudent about that,&#8221; he added. Moravy is Vice President of Vehicle Engineering at Tesla. 
Just a couple of weeks ago, the company made 1000 Cybertrucks in a week, Moravy said. While the company is looking to achieve volume production to bring down costs, it still faces challenges with the many new technologies and supplier limitations, he added. 
Why It Matters: In December,&nbsp;Reuters&nbsp;<a href="https://www.benzinga.com/markets/equities/23/12/36341487/teslas-cybertruck-reportedly-struggles-with-its-pioneering-4680-battery-is-250-000-production-go" target="_blank" rel="noreferrer noopener">reported</a>&nbsp;that the EV giant is struggling to make 4680 cells fast enough to meet its targeted annual delivery rate of a quarter million Cybertrucks. Tesla&#8217;s gigafactory in Texas is making only enough cells for about 24,000 Cybertrucks a year, the report said.
The annual delivery target of 250,000 Cybertrucks, company CEO Elon Musk has previously said, would not be reached this year but only<a href="https://www.benzinga.com/news/23/10/35322048/tesla-ceo-elon-musk-details-enormous-challenges-in-reaching-volume-production-for-cybertruck-we-dug" target="_blank" rel="noreferrer noopener"> in 2025.</a>
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="http://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read More: <a href="https://www.benzinga.com/news/24/04/38395808/teslas-high-profile-departures-continue-as-investor-relations-head-martin-viecha-bids-farewell-after">Tesla&#8217;s High-Profile Departures Continue As Investor Relations Head Martin Viecha Bids Farewell After 7-Year Run</a>
Photo via Shutterstock

Guidance

Tesla Exec Says 1,000 Cybertrucks A Week Prove 4680 Cell Production Isn't A Bottleneck: 'We Expect To Stay Ahead...'

Under the agreement, ANGLE will develop a novel methodology for CTC micronuclei detection based on its existing pKAP1 CTC-based DDR assay, which measures expression of a key protein in the DNA damage response. Assay development will take place in ANGLE&#39;s laboratories in Guildford, UK, and follows the Company&#39;s development and launch of two highly sensitive and specific DDR assays in 2023. The 6-month development phase is worth an initial &pound;150,000 to ANGLE.

ANPCF

Angle Inks New Commercial Agreement With AstraZeneca to Enhance DNA Damage Response Detection

Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) is set to release earnings results for its first quarter after the<a href="https://www.benzinga.com/quote/META/earnings"> closing bell on April 24, 2024.</a>
Analysts expect the Menlo Park, California-based company to report quarterly earnings at $4.32 per share, up from $2.20 per share in the year-ago period. Meta is projected to report quarterly revenue of $36.16 billion, up from $28.64 billion in the year-earlier quarter, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Meta recently announced that its AI assistant, powered by the newly launched Llama 3 model, will now incorporate real-time search results from Alphabet Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google and Microsoft Corp.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) Bing.
Meta shares rose 3% to close at $496.10 on Tuesday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/META/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Bernstein analyst Mark Shmulik maintained an Outperform rating and raised the price target from $535 to $590 on April 18, 2024. This analyst has an accuracy rate of 82%.</li>
<li>Truist Securities analyst Youssef Squali maintained a Buy rating and boosted the price target from $525 to $550 on April 17, 2024. This analyst has an accuracy rate of 81%.</li>
<li>UBS analyst Lloyd Walmsley maintained a Buy rating and raised the price target from $530 to $610 on April 16, 2024. This analyst has an accuracy rate of 85%.</li>
<li>Stifel analyst Mark Kelley maintained a Buy rating and boosted the price target from $527 to $588 on April 16, 2024. This analyst has an accuracy rate of 87%.</li>
<li>Citigroup analyst Ronald Josey maintained a Buy rating and increased the price target from $525 to $590 on April 15, 2024. This analyst has an accuracy rate of 72%.</li>
</ul>
Read This Next: <a href="https://www.benzinga.com/news/24/04/38376630/amazon-com-united-airlines-and-2-other-stocks-insiders-are-selling">Amazon.com, United Airlines And 2 Other Stocks Insiders Are Selling</a>

Price Target

MSFT

Meta Likely To Report Higher Q1 Earnings; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Timberland Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSBK#NASDAQ">TSBK</a>) reported quarterly earnings of $0.70 per share. This is a 12.5 percent decrease over earnings of $0.80 per share from the same period last year. The company reported $18.25 million in sales this quarter. This is a 7.77 percent decrease over sales of $19.79 million the same period last year.

TSBK

Timberland Bancorp Q2 EPS $0.70 Down From $0.80 YoY, Sales $18.25M Down From $19.79M YoY

LPTV

Reported Earlier, NYSE American Issues Non-Compliance Warning To Loop Media For Continued Listing Standards

Management

Reported Earlier, Visionary Holdings Appoints Zhong Chen As CEO, Effective Immediately

Amid fluctuating market conditions and rumors about Elon Musk's role as the CEO of Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), the tech billionaire has suggested that he <a href="https://www.benzinga.com/news/24/04/38288360/breaking-tesla-shareholders-to-vote-again-on-ceo-elon-musks-voided-47b-pay-package">continues to spend</a> the majority of his time at the EV giant. 
What Happened: On Tuesday, during <a href="https://www.benzinga.com/news/earnings/24/04/38390883/tesla-q1-earnings-highlights-ev-giant-misses-wall-street-estimates-makes-cost-cuts-invests-in-ai-sp">Tesla's first-quarter earnings call</a>, Musk was asked that considering he is leading several important companies including SpaceX and X, formerly Twitter, where does his heart actually belong.&nbsp;
The question came from Tony Sacconaghi, a Wall Street analyst from Bernstein, who asked him about the possibility of reduced involvement with Tesla at &#8220;any point over the next three years.&#8221;&nbsp;
In response, Musk sidestepped answering the question directly. He said that Tesla &#8220;constitutes a majority of my work time, and I work pretty much every day of the week, it&#8217;s rare for me to take a Sunday afternoon off.&#8221;
Subscribe to the <a href="https://bztechtrends.beehiiv.com/subscribe">Benzinga Tech Trends newsletter</a> to get all the latest tech developments delivered to your inbox.
The entrepreneur went on to assert that he will make sure &#8220;Tesla is quite prosperous. And it is — like it is prosperous, and it will be very much so in the future.&#8221;
Last year, Tesla director James Murdoch created a stir when he reportedly suggested that <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/11/29760366/is-elon-musk-stepping-down-as-tesla-ceo-soon-analysts-react-to-succession-comments">Musk has identified a potential successor</a> to replace him.&nbsp;
Why It's Important: Earlier this month, Tesla's stock faced a significant downturn following a report on <a href="https://www.benzinga.com/markets/equities/24/04/38047077/tesla-stock-dives-as-q1-deliveries-disappoint-but-ev-giant-reclaims-top-spot-from-chinese-rival">disappointing first-quarter deliveries</a>. At the time, Wedbush analyst Dan Ives said that <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38202377/elon-musk-should-pledge-3-5-year-tenure-as-ceo-says-wedbushs-dan-ives-70-of-the-val">70% of Tesla's value is Musk</a>.&nbsp;
&#8220;Musk is Tesla, Tesla is Musk,&#8221; he said.
In January earlier this year, Musk said that he <a href="https://www.benzinga.com/news/24/01/36634396/elon-musk-seeks-greater-control-over-tesla-as-ai-endeavors-multiply-enough-to-be-influential-not-so">would require increased control of Tesla</a> if he is to advance AI endeavors at the company. &#8220;I am uncomfortable growing Tesla to be a leader in AI &amp; robotics without having ~25% voting control. Enough to be influential, but not so much that I can&#8217;t be overturned.&#8221;
Previously, in 2020, <a href="https://www.benzinga.com/general/24/01/36574844/elon-musk-says-he-never-wanted-to-be-ceo-of-tesla-or-anything-running-companies-hurts-my-heart-but-h">Musk admitted that he never wanted</a> to be CEO of Tesla. &#8220;This is misinterpreted like I somehow don't love Tesla, which I do, it's just like trying not to go insane with work,&#8221; he said at the time.&nbsp;&nbsp;
Check out more of Benzinga's Future Of Consumer Tech by <a href="https://www.benzinga.com/topic/consumer-tech">following this link.</a>
Read Next: <a href="https://www.benzinga.com/news/24/04/38394597/elon-musk-reacts-to-marjorie-taylor-greenes-ally-revelation-of-fine-threat-by-house-authorities-mike">Elon Musk Reacts To Marjorie Taylor Greene&#8217;s Ally Revelation Of Fine Threat By House Authorities: Mike Johnson Removing Traces Of &#8216;Betrayal of America&#8217;</a>

Elon Musk Answers Question On Reducing Involvement At Tesla In Coming 3 Years: 'It's Rare For Me To Take A Sunday Afternoon'

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Vaxart (NASDAQ:<a href="https://investorplace.com/stock-quotes/vxrt-stock-quote/">VXRT</a>) just reported results for the fourth quarter of 2023.<ul><li>Vaxart reported earnings per share of -12 cents. This was above the analyst estimate for EPS of -14 cents.</li><li>The company reported revenue of $3.25 million.</li><li>This was 159.60% better than the analyst estimate for revenue of $1.25 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT793992">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/02/wall-street-legend-issues-urgent-ai-code-red/?cid=MKT781156&amp;eid=MKT793990">&ldquo;America&rsquo;s Top Trader&rdquo; Issues A.I. Code Red: Act Now or Miss Out</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793999">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/03/vxrt-stock-earnings-vaxart-for-q4-of-2023/">VXRT Stock Earnings: Vaxart Beats EPS, Beats Revenue for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

VXRT Stock Earnings: Vaxart Beats EPS, Beats Revenue for Q4 2023

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Vaxart (NASDAQ:<a href="https://investorplace.com/stock-quotes/vxrt-stock-quote/">VXRT</a>) just reported results for the fourth quarter of 2023.<ul><li>Vaxart reported earnings per share of -12 cents. This was above the analyst estimate for EPS of -14 cents.</li><li>The company reported revenue of $3.25 million.</li><li>This was 159.60% better than the analyst estimate for revenue of $1.25 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/03/vxrt-stock-earnings-vaxart-for-q4-of-2023/">VXRT Stock Earnings: Vaxart Beats EPS, Beats Revenue for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Vaxart Inc (VXRT) said after close Thursday that it lost $0.12 per share in quarter four 2023. On the revenue line, the company reported $3.2 million, beating estimates by $2 million.In the same quarter a year ago, the company lost $0.18 per share on revenue of $22 thousand. The stock is up 4.55% to $1.15 after the report.

Vaxart Inc Up 4.55% To $1.15 After Earnings Beat

In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Vaxart (VXRT – Research Report), with a price target o...

Buy Rating Affirmed for Vaxart Amid Promising Vaccine Trials and Strategic Advancements

Vaxart Inc (VXRT) has risen Thursday morning, with the stock climbing 9.30% in pre-market trading to 1.41. VXRT's short-term technical score of 54 indicates that the stock has traded more bullishly over the last month than 54% of stocks on the market. In the Biotechnology industry, which ranks 104 out of 146 industries, Va

Premarket Mover: Vaxart Inc (VXRT) Up 9.30%

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
The 2024 presidential election is shaping up to be just as exciting and contentious the 2020 contest. That&rsquo;s because it looks to be a rematch between President Biden and former President Trump. There&rsquo;s a wildcard thrown in this time with Robert Kennedy Jr. running an independent campaign that could pull voters from both sides.



The stock market went on a rollercoaster ride four years ago. A decade-long bull market was brought up short by the pandemic. The S&amp;P 500 lost one-third of its value in a matter of weeks only to make a U-turn and soar higher once more. It wasn&rsquo;t uncommon to see stocks soar by 1,000% or more.



These are the seven top 2020 stocks that didn&rsquo;t end up crashing and becoming <a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a>. Can they repeat their prized performance from four years ago? Let&rsquo;s find out!



<h2>Novavax (NVAX)&nbsp;</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/nvax_novavax1600-300x169.png" alt="Novavax (NVAX) research laboratory logotype enlarged with a magnifying glass.This laboratory has developed a vaccine against the covid-19 virus. NVAX price predictions."><div>Source: pixinoo / Shutterstock.com</div></div>The pandemic, of course, was the defining moment of 2020. Not only for the devastation it caused in our lives but also for the opportunity it created for companies to rise to the challenge. Novavax (NASDAQ:<a href="https://investorplace.com/stock-quotes/nvax-stock-quote/">NVAX</a>) shocked everyone when the Operation Warp Speed committee <a href="https://ir.novavax.com/press-releases/2020-07-07-Novavax-Announces-1-6-Billion-Funding-from-Operation-Warp-Speed">granted it $1.6 billion</a> in federal funds to develop a Covid-19 vaccine. It was more than any other drugmaker was given at the time. Its vaccine candidate had the best potential in testing ahead of even Pfizer (NYSE:<a href="https://investorplace.com/stock-quotes/pfe-stock-quote/">PFE</a>) and Moderna (NASDAQ:<a href="https://investorplace.com/stock-quotes/mrna-stock-quote/">MRNA</a>). It hadn&rsquo;t undergone human testing at the time but preliminary results in primates looked promising.



As we all know, both Pfizer (and its partner BioNTech (NASDAQ:<a href="https://investorplace.com/stock-quotes/bntx-stock-quote/">BNTX</a>) and Moderna went to market first. They were given emergency use authorization (EUA) for their experimental vaccines and shielded from liability for any damages for harm caused by them. Today, myocarditis &mdash; a potentially deadly inflammation of the heart muscle &mdash; is more common in <a href="https://bmjopen.bmj.com/content/13/6/e065687">people who received Covid vaccines</a> than those who are unvaccinated.



Novavax, though, would be late in releasing its own vaccine. NVAX stock soared 2,695% in 2020, and tripled again in early 2021, ultimately plummeting back to earth. From it&rsquo;s all-time high of $320 per share, Novavax trades at around $4.40 per share today. While it has a combination Covid and flu vaccine in development, <a href="https://investorplace.com/2024/01/time-to-buy-these-3-stocks-that-just-hit-a-52-week-low/">there seems little chance</a> it will repeat as a top performer this year.



<h2>HIVE Digital Technologies (HIVE) </h2>



<div><img width="300" height="165" src="https://investorplace.com/wp-content/uploads/2018/04/datacentermsn-300x165.jpg" alt="Image of a well-lit data center"><div>Source: Shutterstock</div></div>Back then, HIVE Digital Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/hive-stock-quote/">HIVE</a>) was known as HIVE Blockchain Technologies. It changed its name last year to better reflect its new <a href="https://finance.yahoo.com/news/hive-blockchain-announces-rebranding-name-050000554.html">focus on high-performance computing data centers</a>. It was another stock that generated enormous returns in 2020 only to go on and soar even higher the following year.



At the time, though, it was all about bitcoin mining as Bitcoin (<a href="https://investorplace.com/cryptocurrency/btc-usd/">BTC-USD</a>) was blowing through the $20,000 price threshold. Mining stocks were seen as an attractive way for investors to get exposure to Bitcoin&rsquo;s price in a relatively risk-free way because they were seen as cryptocurrency infrastructure stocks.



Bitcoin mining isn&rsquo;t anywhere near as popular today. It&rsquo;s why HIVE Digital is no longer HIVE Blockchain. Particularly as the <a href="https://www.reuters.com/technology/what-is-bitcoins-halving-does-it-matter-2024-03-13/#:~:text=Miners%20use%20computing%20power%20to,the%20production%20of%20new%20bitcoins.">Bitcoin halving event </a>will make mining even less profitable than it is now because it will slow the production of new Bitcoin.



HIVE Digital soared 2,507% in 2020 and doubled again in February, hitting almost $21 a share. It has since lost 88% of its value and trades at around $3.30 per share. No amount of rebranding will turn around its fortunes this year.



<h2>Blink Charging (BLNK)&nbsp;</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/04/blnk-stock-300x169.jpg" alt="a blink charging station, BLNK stock"><div>Source: David Tonelson/Shutterstock.com</div></div>Make it three in a row with Blink Charging (NASDAQ:<a href="https://investorplace.com/stock-quotes/blnk-stock-quote/">BLNK</a>), which began to ramp higher in 2020 only to reach its apex in 2021. Afterward, it would begin a long slog lower.



The electric vehicle (EV) charging equipment provider as the EV industry was hot and the need for charging stations was strong. Blink Charging ended 2020 with over <a href="https://www.sec.gov/Archives/edgar/data/1429764/000149315221007550/form10-k.htm#ps_010">16,600 charging stations installed</a>, of which 7,062 were on the Blink Network. That was a 12% increase over the year before.



Revenue had tripled to $6.2 million while gross profits rose four-fold to $1.5 million giving it 24% gross margins. Blink was still a loss-generating business, and net losses had almost doubled to $17.8 million, but it was seen as well on the path to a bright future. The stock rocketed 2,186% higher that year.



Today the EV industry is in a different place. While still expanding, demand is rapidly shrinking globally and EV makers are resorting to price-cutting to lure buyers in. It&rsquo;s not a healthy situation and one that has <a href="https://investorplace.com/2024/01/reality-check-ai-predicts-these-3-stocks-can-10x-in-5-years-heres-why-they-wont/">cooled the momentum</a> for charging station stocks. Blink Charging sunk from over $60 a stub to below $3 a share.



<h2>Vaxart (VXRT)&nbsp;</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/05/vaxart_vxrt_1600_d-300x169.jpg" alt="VXRT stock: A photo of a person wearing gloves holding a bottle of pills."><div>Source: Photo courtesy of Vaxart, Inc.</div></div>Okay, make it four companies. Biotech Vaxart (NASDAQ:<a href="https://investorplace.com/stock-quotes/vxrt-stock-quote/">VXRT</a>) has seen several massive spikes in its stock. It started 2020 as a tiny penny stock but the pandemic help it burst onto the scene. Jumping onto the vaccine bandwagon, Vaxart announced it was pursuing an oral vaccine for Covid and the stock made its way from 34 cents per share all the way up to $17 a share. And just as quickly plummeted back down to around $1 per share. It closed out the year under $6 a share making for a nice 1,600% gain.



It would be a repeat performance in 2021 when it rocketed to over $23 a share after announcing <a href="https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-positive-preliminary-data-phase-1-clinical">positive phase 1 results</a> from its investigational VXA-CoV2-1 vaccine. At this point though, Vaxart was well behind the pack in developing a Covid vaccine. Both Pfizer and Moderna had released their vaccines two months prior. Vaxart&rsquo;s therapy is still in Phase II testing.&nbsp;



With that said, as Vaxart notes, &ldquo;it is now the only company to have taken an oral tablet COVID-19 to a Phase II clinical trial.&rdquo; Pfizer and Moderna essentially conducted an experiment on the entire global population. They only operated under the EUA and have <a href="https://www.latimes.com/science/story/2020-12-12/why-fda-didnt-approve-pfizer-covid-19-vaccine-eua">never gotten traditional FDA approval</a> for their shots. If Vaxart&rsquo;s ever makes it through to the end it may be the first to achieve a positive result through rigorous testing.



<h2>Riot Platforms (RIOT)&nbsp;</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/07/riot1600-300x169.png" alt="In this photo illustration, the Riot Platforms (RIOT) logo is displayed on a smartphone screen."><div>Source: rafapress / Shutterstock.com</div></div>It wasn&rsquo;t just HIVE Blockchain undergoing a reimagining after the Bitcoin mining mania wore off. Riot Blockchain <a href="https://www.globenewswire.com/en/news-release/2023/01/03/2582242/0/en/Riot-Blockchain-Inc-Announces-Corporate-Rebranding-to-Riot-Platforms-Inc.html">also changed its name</a> last year, becoming Riot Platforms (NASDAQ:<a href="https://investorplace.com/stock-quotes/riot-stock-quote/">RIOT</a>). It&rsquo;s purpose was to reflect its growth strategy and the diversified nature of its operations, though Riot&rsquo;s goal is still to be &ldquo;the world&rsquo;s leading Bitcoin-driven infrastructure platform.&rdquo;



Shrinking profit margins were turning investors off to mining operations, so rebranding as &ldquo;digital&rdquo; or becoming a &ldquo;platform&rdquo; took the sting away from the association. Applied Blockchain also transformed into Applied Digital (NASDAQ:<a href="https://investorplace.com/stock-quotes/apld-stock-quote/">APLD</a>) for much the same reasons. <a href="https://www.theblock.co/post/198907/bitcoin-miner-riot-platforms-drops-blockchain-in-rebrand">Many others did so as well</a>.



While it was still a mining operation though, Riot rode the intense investor enthusiasm to a 1,390% gain in 2020. It would reach its all-time high just two weeks later, cresting at $29 before losing two-thirds of its value. Today Riot Platforms stock trades at $10 a stub as no amount of rebranding can turn the business around.



<h2>Cardiff Oncology (CRDF)&nbsp;</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/08/srne_doctor_oncology_1600-300x169.jpg" alt="A doctor points at an abstract representation of various aspects of oncology. SHPH stock"><div>Source: Oleg Ivanov IL / Shutterstock.com</div></div>Biotech Cardiff Oncology (NASDAQ:<a href="https://investorplace.com/stock-quotes/crdf-stock-quote/">CRDF</a>) didn&rsquo;t rise to glory in 2020 on the back of the Covid pandemic. Rather, as its name implies, it had bigger fish to fry in cancer. Its lead molecule, onvansertib, was a unique opportunity because it was targeting cancer caused by the KRAS mutation. That is an <a href="https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/symptoms-diagnosis/biomarker-testing/kras">error in a normal cell protein</a> that signals the body to produce more cells, which turns into cancer.&nbsp;



Although there are other drug developers focused on the KRAS mutation, including Amgen (NASDAQ:<a href="https://investorplace.com/stock-quotes/amgn-stock-quote/">AMGN</a>), this was Cardiff&rsquo;s only drug and if successful, it would have been a multi-billion opportunity. Shares soared 1,328% in 2020 on that potential.



CRDF stock ran higher again in 2021 as well after some promising, though mixed results in early phase testing caused the stock to stumble. It would go on to fall further in 2022 as additional results also showed promise but underwhelmed the market. But it&rsquo;s off to the races again in 2024!



Cardiff Oncology stock is up 300% so far this year and is nearly 400% higher over the past six months. Virtually all of the gains came in just the last months after the drug developer <a href="https://www.globenewswire.com/news-release/2024/02/29/2838410/0/en/Cardiff-Oncology-Provides-Clinical-Update-on-Phase-2-Randomized-Second-line-ONSEMBLE-Trial-in-Patients-with-RAS-mutated-mCRC.html">reported positive results</a> from testing. As of this writing CRDF stock is in the top 20 of stock performance this year meaning there&rsquo;s a good chance it can repeat its winning results of 2020.



<h2>Nio (NIO) </h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/10/nio1600-6-300x169.png" alt="Nio Chinese automobile manufacturer logo displayed on mobile phone"><div>Source: Piotr Swat / Shutterstock.com</div></div>Unfortunately, Chinese EV maker Nio (NYSE:<a href="https://investorplace.com/stock-quotes/nio-stock-quote/">NIO</a>) isn&rsquo;t likely to do so. It will more likely mimic the performance of Blink Charging than Cardiff. As noted before, the EV industry is in a state of flux. With <a href="https://investorplace.com/2024/04/3-tech-stock-titans-grappling-with-fresh-china-challenges/">sales growth ebbing</a>, this back-of-the-pack EV stock isn&rsquo;t going to suddenly charge to the forefront.



Nio is also not profitable, so the ongoing price-cutting environment will only set Nio&rsquo;s chances back even further. But in 2020 it didn&rsquo;t look that way at all.



Where most other EV companies were building sedans, Nio was making SUVs and finding a market for them. Even amid the pandemic, which China responded to far more harshly than Western governments did, Nio was steadily growing monthly sales and had secured financing from Tencent Holdings (OTCMKTS:<a href="https://investorplace.com/stock-quotes/tcehy-stock-quote/">TCEHY</a>) and the government. Nio stock soared 1,089% in 2020.



After hitting an all-time high of $63 a share in early 2021, Nio long ago <a href="https://investorplace.com/2024/02/nio-stock-analysis-a-high-octane-gamble-or-smart-speculative-play/">skidded off the road</a>. The stock goes for less than $4.50 a share today and nothing suggests it&rsquo;s about to rev its engines higher.



On the date of publication, Rich Duprey did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.
<div>Rich Duprey has written about stocks and investing for the past 20 years. His articles have appeared on Nasdaq.com, The Motley Fool, and Yahoo! Finance, and he has been referenced by U.S. and international publications, including MarketWatch, Financial Times, Forbes, Fast Company, USA Today, Milwaukee Journal Sentinel, Cheddar News, The Boston Globe, L&rsquo;Express, and numerous other news outlets.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/04/election-year-encore-can-2020s-top-7-stock-winners-repeat-their-performance-in-2024/">Election Year Encore: Can 2020&#8217;s Top 7 Stock Winners Repeat Their Performance in 2024?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Election Year Encore: Can 2020's Top 7 Stock Winners Repeat Their Performance in 2024?

AMGN

APLD

BLNK

BNTX

CRDF

HIVE

MRNA

NVAX

RIOT

TCEHY

Press Releases

Vaxart, Inc. Announces Management Change

Financing

Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management

Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Health Care

Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge

Opinion

Thinking about buying stock in Cano Health, Vaxart, Macy's, Albemarle Corp, or BioXcel Therapeutics?

Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director

Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14